| ²é¿´: 442 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
shuxinme111½ð³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
Ò»¾ä»°·Òë¡«¡«¡«
|
||
|
To address the primary hypothesis, the mean change from baseline in A1C produced by the addition of sitagliptin treatment at Week 24 in the entire cohort will be compared to that of placebo using the least-squares (LS) means of the sitagliptin and placebo treatment groups as estimated via analysis of covariance (ANCOVA). Ö÷Òª²»ÊǺÜÀí½âºóÃæas estimated via analysis of covariance (ANCOVA). µÄÒâ˼£¬µ½µ×ÊÇÓÃLS»¹ÊÇANCOVA½øÐа¡£¿£¿£¿ÇóÖ¸µã¡«¡«¡« |
» ²ÂÄãϲ»¶
»¹Óл¯¹¤¶þÂÖµ÷¼ÁµÄѧУÂð
ÒѾÓÐ18È˻ظ´
283Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
299Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏר˶³õÊÔ·Ö332Ò»Ö¾Ô¸Î÷±±¹¤Òµ´óѧ£¬
ÒѾÓÐ8È˻ظ´
²ÄÁϹ¤³Ì085601£¬270Çóµ÷¼Á
ÒѾÓÐ28È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ21È˻ظ´
Ò»Ö¾Ô¸ÎäÀí³µÁ¾ 281 Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
085404 293Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
¹¤¿Æ273µ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏ295
ÒѾÓÐ16È˻ظ´
liufuliang
гæ (ÖªÃû×÷¼Ò)
- ·ÒëEPI: 19
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 61.9
- É¢½ð: 1273
- ºì»¨: 4
- ɳ·¢: 1
- Ìû×Ó: 7909
- ÔÚÏß: 274.7Сʱ
- ³æºÅ: 98678
- ×¢²á: 2005-11-10
- ÐÔ±ð: GG
- רҵ: ²¡Ôϸ¾úÓë·ÅÏß¾úÉúÎïѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
Mally89: ½ð±Ò+1, ¸ÐлӦÖú£¡~»¶Ó³£À´£¡~ºðºð£¡~\(^o^)/~ 2012-03-16 22:13:34
shuxinme111: ½ð±Ò+8, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú, thank you~~~~ллÄãµÄ·ÖÎö¡«¡«¡« 2012-03-21 21:01:01
Mally89: ½ð±Ò+1, ¸ÐлӦÖú£¡~»¶Ó³£À´£¡~ºðºð£¡~\(^o^)/~ 2012-03-16 22:13:34
shuxinme111: ½ð±Ò+8, ·ÒëEPI+1, ¡ï¡ï¡ïºÜÓаïÖú, thank you~~~~ллÄãµÄ·ÖÎö¡«¡«¡« 2012-03-21 21:01:01
|
using the least-squares (LS) means of the sitagliptin and placebo treatment groups as estimated via analysis of covariance (ANCOVA). ºóÃæµÄ2¸ö²¿·ÖÊDz¢Áеģ¬Ê¹Óà least-squares (LS) means of the sitagliptin ºÍ placebo treatment groups as estimated via analysis of covariance (ANCOVA). ºóÃæµÄ as estimated via analysis of covariance (ANCOVA). ÊÇÐÞÊÎplacebo treatment groups ¡£ |

2Â¥2012-03-16 16:07:25













»Ø¸´´ËÂ¥